Selected Publications
As of May 29, 2009
Simon R, Freidlin B, Rubinstein L, Arbuck
S, Collins J, Christian M. Accelerated Titration Designs for Phase
I Clinical Trials in Oncology. Journal of the National Cancer
Institute 89, 1138-1147, 1997.
Smith M, Freidlin B, Gloeckler Reis LA, and Simon
R. Trends in the Reported Incidence of Primary Malignant Brain Tumors
in Children in the United States. Journal of the National Cancer
Institute 90, 1269-1277, 1998.
Freidlin B, Gastwirth, JL. Unconditional Versions
of Several Tests Commonly Used in the Analysis of Contingency Tables.
Biometrics 55, 84-89. 1999.
Freidlin B, Podgor MJ, Gastwirth JL. Efficiency Robust
Tests for Survival and Ordered Categorical Data. Biometrics 55,
883-886, 1999.
Freidlin B, Korn EL and George SL. Data monitoring
committees and interim monitoring guidelines. Controlled Clinical
Trials 20, 395-407, 1999.
Freidlin B, and Gastwirth JL. Should the median test
be retired from the general use? American Statistician
54, 161-164, 2000.
Freidlin B and Korn EL A testing procedure for survival
data with few responders. Statistics in Medicine 21, 65-78,
2002.
Freidlin B and Korn EL A comment on futility monitoring. Controlled Clinical Trials 23, 355-356, 2002.
Freidlin B, Zheng G, Li Z, Gastwirth JL. Trend tests for case-control studies of genetic markers: power, sample size and robustness. Human Heredity, 53 146-152, 2002.
Freidlin B, Zheng G, Li ZH, Gastwirth JL. Efficiency robust tests for mapping quantitative trait loci using extremely discordant sib pairs. Human Heredity 55, 117-124, 2003.
Freidlin B, Korn EL. Testing treatment effects in the presence of competing risks. Statistics in Medicine 24, 1703-1712, 2005.
Freidlin B, Simon R. An evaluation of randomized discontinuation design. Journal of Clinical Oncology 23, 5094-5098. 2005
Freidlin B, Simon R. Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clinical Cancer Research 11:7872-7878. 2005.
Korn EL, Freidlin B. Conditional power calculations for clinical trials with historical controls. Statistics in Medicine 25:2922-2931, 2006.
Freidlin B, Korn EL. Release of data from an ongoing randomized clinical trial for sample size adjustment or planning. Statistics in Medicine 26:4074-4082, 2007.
Freidlin B, Korn EL, Hunsberger S, Gray R, Saxman S, Zujewski JA. Proposal for the use of progression-free survival in unblinded randomized trials. Journal of Clinical Oncology 25:2122-6, 2007.
Jiang W, Freidlin B, Simon R. Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. Journal of the National Cancer Institute 99:1036-43, 2007.
Freidlin B, Korn EL, George SL, Gray R. Randomized clinical trial design for assessing non-inferiority when superiority is expected. Journal of Clinical Oncology 25: 5019-5023, 2007.
Korn EL and Freidlin B. A note on controlling the number of false positives. Biometrics 64:227-231, 2008.
Freidlin B, Korn EL, Gray R, Martin A. Multi-arm clinical trials of new agents: some design considerations. Clinical Cancer Research 14:4368-71, 2008
Dodd LE, Korn EL, Freidlin B, Jaffe CC, Rubinstein LV, Dancey J, Mooney MM. Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? Journal of Clinical Oncology 26:3791-6, 2008.
Freidlin B, Korn EL. Monitoring for Lack of Benefit: A Critical Component of a Randomized Clinical Trial Journal of Clinical Oncology 27:629-33, 2009.
Korn EL, Freidlin B, Mooney M. Stopping or Reporting Early for Positive Results in Randomized Clinical Trials: The NCI Cooperative Group Experience 1990-2005 Journal of Clinical Oncology 27:1543-4, 2009.
Freidlin B, Korn EL. Stopping clinical trials early for benefit: impact on estimation. Clinical Trials 6:119-25, 2009.
brb@linus.nci.nih.gov